Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of oral microencapsulated ragweed pollen extract over one year
2007-004538-18Phase 3Terminated
- Sponsor
- Curalogic
- Start
- Oct 2007
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ragweed allergy comparing MRPE 40 Amb a 1 units daily with Placebo (2 arms). Primary endpoint: Safety of MRPE over 1 year. Started Oct 2007; status: terminated.
02
Drugs
microencapsulated ragweed pollen extract
03
Conditions
ragweed allergy
Beyond the preview
Go deeper on 2007-004538-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004538-18.